Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 12/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1263156 | 1.00 | KIF11 (0.61) | KIF11KCNH2SLC6A1SLC6A11CYP2C9 | |
| SCHEMBL26068376 | 1.00 | KIF11 (0.61) | KIF11KCNH2SLC6A1SLC6A11CYP2C9 | |
| Succinic Acid SCHEMBL6854675 | 0.92 | KIF11 (0.54) | KIF11KCNH2SLC6A1SLC6A11 | |
| SCHEMBL16214813 | 0.85 | KIF11 (0.50) | KIF11KCNH2SLC6A1SLC6A11CYP2C9 | |
| SCHEMBL13388489 | 0.85 | KIF11 (0.50) | KIF11KCNH2SLC6A1SLC6A11 | |
| SCHEMBL3487683 | 0.85 | KIF11 (0.50) | KIF11KCNH2SLC6A1SLC6A11CYP2C9 | |
| SCHEMBL9508740 | 0.84 | KIF11 (0.49) | KIF11KCNH2SLC6A1SLC6A11 | |
| SCHEMBL3490250 | 0.84 | KIF11 (0.49) | KIF11KCNH2SLC6A1SLC6A11TSHR | |
| SCHEMBL15281845 | 0.84 | KIF11 (0.49) | KIF11KCNH2SLC6A1SLC6A11TSHR | |
| SCHEMBL20371097 | 0.82 | KIF11 (0.50) | KIF11KCNH2SLC6A1SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017178656-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2017-10-19 | — | — | WO | disclosed |
| US-7705136-B2 | Synthesis of 3′-, or 5′-, or internal methacrylamido-modified oligonucleotides | UCHICAGO ARGONNE, LLC (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060194213-A1 | Synthesis of 3'-, or 5'-, or internal methacrylamido-modified oligonucleotides | U CHICAGO ARGONNE LLC | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194213-A1 | Synthesis of 3'-, or 5'-, or internal methacrylamido-modified oligonucleotides | NSUN2, RNGTT, BCDIN3D | KIF11 2591/4885KCNH2 4837/4885SLC6A1 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.